Differential Protein Expression in Congenital and Acquired Cholesteatomas

Seung-Ho Shin¹,²*, Mei Huang³*, Sung Huhn Kim⁴‡*, Jae Young Choi⁴‡*

¹ Department of Otorhinolaryngology–Head and Neck Surgery, School of Medicine, Ewha Womans University, Seoul, Korea, ² Department of Medicine, Graduate School, Yonsei University, Seoul, Korea, ³ Research Center for Human Natural Defense System, Yonsei University College of Medicine, Seoul, Korea, ⁴ Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea

☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* jychoi@yuhs.ac (JYC); fledermaus@yuhs.ac (SHK)

Abstract

Congenital cholesteatomas are epithelial lesions that present as an epithelial pearl behind an intact eardrum. Congenital and acquired cholesteatomas progress quite differently from each other and progress patterns can provide clues about the unique origin and pathogenesis of the abnormality. However, the exact pathogenic mechanisms by which cholesteatomas develop remain unknown. In this study, key proteins that directly affect cholesteatoma pathogenesis are investigated with proteomics and immunohistochemistry. Congenital cholesteatoma matrices and retroauricular skin were harvested during surgery in 4 patients diagnosed with a congenital cholesteatoma. Tissue was also harvested from the retraction pocket in an additional 2 patients during middle ear surgery. We performed 2-dimensional (2D) electrophoresis to detect and analyze spots that are expressed only in congenital cholesteatomas. Of these 127 spots, 10 major spots revealed the presence of titin, forkhead transcription activator homolog (FKH 5–3), plectin 1, keratin 10, and leucine zipper protein 5 by MALDI-TOF/MS analysis. Immunohistochemical staining showed that FKH 5–3 and titin were expressed in congenital cholesteatoma matrices, but not in acquired cholesteatomas. Our study shows that protein expression patterns are completely different in congenital cholesteatomas, acquired cholesteatomas, and skin. Moreover, non-epithelial proteins, including FKH 5–3 and titin, were unexpectedly expressed in congenital cholesteatoma tissue. Our data indicates that congenital cholesteatoma origins may differ from those of acquired cholesteatomas, which originate from retraction pocket epithelia.
Introduction

A congenital cholesteatoma is a keratinized squamous epithelial middle ear lesion that usually presents in young children who do not have a history of otitis media, middle ear surgery, or trauma. The presentation and progress of congenital cholesteatoma are quite different from those of acquired cholesteatoma. Congenital cholesteatomas commonly appear as pearl-like epidermoid cysts, mostly located in the antero-superior quadrant behind an intact tympanic membrane [1, 2]. These cholesteatomas can have invasive growth and cause osteolysis [3].

The pathogenesis of congenital cholesteatomas seems to be different from acquired cholesteatomas, which usually arise from the retraction pocket of the pars flaccida of tympanic membrane and have attic destruction [4, 5]. Several pathogenic mechanisms of congenital cholesteatoma have been suggested, including epithelial rests from faulty embryogenesis, invagination or implantation of squamous epithelium, and metaplasia of middle ear epithelium [6]. These suggested pathogenic mechanisms are based on temporal bone histology studies [7–12]. There have been several studies that investigated differences in molecular properties between congenital and acquired cholesteatomas. Upregulation of P21, shorter telomere length, increased surviving expression, and absence of ICAM-1 expression and LFA-1 positive cells have all been suggested to play a role in congenital cholesteatoma pathogenesis. Unfortunately, their exact roles have not been fully identified [3–5, 13]. These studies investigated several target proteins, but no reports have identified differences in molecular expression between congenital and acquired cholesteatoma by mass screening of proteins in each tissue, largely because of the lack of an ideal animal model and a limited number of specimens, which restricted basic molecular and biochemical research on congenital cholesteatoma pathogenesis.

Here, we investigate differences in protein expression between congenital and acquired cholesteatomas using proteomic analysis (for protein mass screening) and immunohistochemistry. Our data suggest that protein expression patterns in congenital cholesteatomas are quite different from those in acquired cholesteatomas and skin. The results of our study may provide clues that allow for a better understanding of congenital cholesteatoma pathogenesis.

Materials and Methods

Tissue harvest

Patients were enrolled in this study after they or their parents provided written informed consent. This study was approved by the institutional review board of Severance Hospital. Samples of congenital cholesteatoma and retroauricular skin were harvested from 6 male children between 4 and 5 year old. All congenial cholesteatomas presented as spherical epithelial pearls behind an intact eardrum in the anterior superior quadrant (Fig 1). In all cases, the congenital cholesteatoma was removed from the middle ear cavity without damaging its capsule. The tympanomeatal flap was elevated using the retroauricular approach. A small amount of retroauricular skin (5 mm x 3 mm ellipsoid) was harvested as a control sample. Samples of acquired cholesteatomas in the pars flaccida area of tympanic membrane were also harvested from 2 adult patients during tympanomastoid surgery (Table 1).

Four harvested samples (subject 1–4 in Table 1) were placed in a small tube, immediately frozen in liquid nitrogen, and stored at -80°C until the time of experiment for proteomic analysis. Two samples for immunohistochemistry (subject 5 and 6 in Table 1) studies were stored in 4% paraformaldehyde. All samples were gently washed with normal saline 3–4 times to remove contaminated tissue and blood.
Fig 1. A representative case of congenital cholesteatomas examined in this study (Patient 2 in Table 1). A. Otoscopic tympanic membrane findings. B. Axial computed tomography image of the temporal bone. C. Surgical findings. D. Congenital cholesteatoma specimen obtained in surgery (scale bar: 5mm).

doi:10.1371/journal.pone.0137011.g001

Table 1. Study subjects and specimen descriptions.

| Subject No. | Gender/age | Specimen type | Specimen description               |
|-------------|------------|---------------|------------------------------------|
| 1           | Male/4 years | CC and RAS   | 3.0 mm diameter epithelial pearl   |
| 2           | Male/4 years | CC and RAS   | 2.5 mm diameter epithelial pearl   |
| 3           | Male/4 years | CC and RAS   | 3.5 mm diameter epithelial pearl   |
| 4           | Male/5 years | CC and RAS   | 3.0 mm diameter epithelial pearl   |
| 5           | Male/5 years | CC and RAS   | 3.5 mm diameter epithelial pearl   |
| 6           | Male/5 years | CC and RAS   | 3.0 mm diameter epithelial pearl   |
| 5           | Female/29 years | AC    | 2 x 2 mm retraction pocket          |
| 6           | Female/51 years | AC   | 2 x 3 mm retraction pocket          |

AC, acquired cholesteatoma; CC, congenital cholesteatoma; RAS, retroauricular skin.

doi:10.1371/journal.pone.0137011.t001
Sample preparation for 2-Dimensional Electrophoresis

Samples for 2-dimensional electrophoresis (2-DE) were suspended in 4x sample buffer (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% ampholyte, 100 mM dithiothretol, 40 mM Tris, 0.002% bromophenol blue) and sonicated. Then, 10μM DNase solution was added and the sample was incubated for 30 minutes at 4°C. After incubation, samples were centrifuged (105,000 G) for 45 minutes. Next, 50% trichloroacetic acid (TCA; Sigma, St. Louis, MO, USA) was added to obtain a final TCA concentration of 5–8%. Samples were then incubated for 2 hours on ice. After incubation, 200 μL of cold acetone was added and the protein pellet was resuspended with a pipette. Samples were again incubated on ice for 15 minutes and centrifuged (14,000 G) for 20 minutes, after which the acetone was discarded. Finally, the protein pellet was air-dried and dissolved in 200 μL sample buffer for quantification with Bradford methods.

Two-Dimensional Electrophoresis

All 2-DE was performed as described [14]. Briefly, aliquots in sample buffer (260 μg) were applied to immobilized pH 3–10 nonlinear gradient strips (Amersham Biosciences, Uppsala, Sweden). Isoelectric focusing was performed at 80,000 Vh. The second dimension was analyzed on 9–16% linear gradient polyacrylamide gels (18 cm × 20 cm × 1.5 cm) at a constant 40 mA per gel for 5 hours. After protein fixation in 40% methanol and 5% phosphoric acid for 1 hour, gels were stained with Coomassie Brilliant Blue G-250 for 12 hours. Gels were then destained with H2O, scanned in a Bio-Rad GS710 densitometer (Bio-Rad, Hercules, CA, USA), and converted into electronic files (12 bit tiff).

2-DE image analysis

Detection of individual spots and measurement of their volume (%) was performed with Image Master Platinum 5 software (GE Healthcare, Piscataway, NJ). Protein spots exclusively identified in congenital cholesteatoma samples were analyzed.

Protein Identification with Mass Spectrometry

Among the exclusive spots identified by 2-DE image analysis, protein components of the 10 most prominent spots were investigated using matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS). For 2-DE gel mapping, major proteins were identified by mass finger printing. Protein spots excised from 2-DE gels were destained, reduced, alkylated, and digested with trypsin (Promega, Madison, WI), as previously described [15]. For MALDI-TOF MS analyses, peptides were concentrated with a POROS R2, Oligo R3 column (Applied Biosystems, Foster city, CA, USA). After washing the column with 70% acetonitrile, 100% acetonitrile, and 50 mM ammonium bicarbonate, samples were applied to the R2, R3 column and eluted onto the MALDI plate (Opti-TOF 384-well Insert, Applied Biosystems) with cyano-4-hydroxycinnamic acid (CHCA; Sigma, St. Louis, MO) dissolved in 70% acetonitrile and 2% formic acid [16]. MALDI-TOF MS was performed on 4800 MALDI-TOF/TOF Analyzer (Applied Biosystems) equipped with a 355 nm Nd:YAG laser. The pressure in the TOF analyzer was approximately 7.6 x 10⁻⁷ Torr. Mass spectra were obtained in the reflectron mode with an accelerating voltage of 20 kV, summed from 500 laser pulses, and calibrated using the 4700 calibration mixture (Applied Biosystems). Proteins were identified from the peptide mass maps using MASCOT (http://www.matrixscience.com/search_form_select.html), which searched the 115,818 entries in the protein databases of the National Center for Biotechnology Information (NCBI) non-redundant human database (downloaded on 05/09/2009).
Immunohistochemical staining

To confirm titin and FKH 5–3 protein expression in congenital cholesteatomas, tissues were fixed with 4% paraformaldehyde for 24 hours, dehydrated, and embedded in paraffin. Paraffin blocks were sectioned into 5 μm thick slices and fixed with a chilled 1:1 mixture of methanol:acetone for 5 minutes after pretreatment with 0.3% H₂O₂ for 20 minutes at room temperature. Slides were treated with 1:600 normal rabbit serum for 20 minutes to block nonspecific reactions and then incubated with a polyclonal antibody against target human proteins, including titin (1:200, HPA007042, Sigma, St. Louis, MO, USA) and forkhead transcription activator homolog (1:200, clone FKH 5–3, human (fragment), AHP933, AbD Serotec, Kidlington, England). Slides were then incubated with biotinylated antihuman rabbit immunoglobulin G (1:200; Vector Laboratories, Burlingame, CA, USA). For negative controls, the step in which samples were reacted with primary antibodies (titin and clone FKH 5–3) was skipped. Peroxidase was attached to the secondary antibody by avidin-biotin peroxidase complex formation. Specimens were incubated in diaminobenzidine tetrahydrochloride to detect primary antibody binding sites.

Results

Differential protein expression in congenital cholesteatoma, acquired cholesteatoma, and external canal skin

The 2-DE analysis of the four congenital cholesteatoma samples showed very similar protein expression patterns (Fig 2) that were quite different from acquired cholesteatoma and retroauricular skin samples (Fig 3). A total of 556 spots were identified in congenital cholesteatomas from 2-DE images analysis. Of the 556 spots, 270 were also simultaneously expressed in acquired cholesteatoma and EAC skin. Additionally, 103 and 56 spots were expressed in skin and acquired cholesteatoma, respectively. Finally, 127 spots were only expressed in congenital cholesteatoma (Fig 4).

Main proteins expression in congenital cholesteatoma

The MALDI-TOF MS analyses were performed to identify the 10 most abundant spots (out of 127 spots) that were only expressed in congenital cholesteatoma (Fig 5). These proteins are summarized in Table 2 and included titin (gi|407139), PRO2619 (gi|11493459), forkhead transcription activator homolog (gi|477361, FHK 5–3), ryanodine receptor 2 isoform CRA_c (gi|119590477), plectin 1 intermediate filament binding protein (gi|119602578), keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris, gi|119581085), keratin 10 (gi|186629), keratin 10 (gi|119581085), titin (gi|407139), and leucine zipper protein 5 isoform CRA_b (gi|119624991).

Forkhead transcription factor (FKH 5–3) and titin expression in congenital cholesteatoma

Among the proteins confirmed by MALDI-TOF MS, FKH 5–3 and titin proteins were selected based on antibody availability and connection probability between previously described pathogenesis and known protein characteristics. Immunolocalization demonstrated that FKH 5–3 and titin were localized in the cell membrane and cytoplasm in all layers of congenital cholesteatoma keratinocytes (Fig 6).
Recent studies of cholesteatoma have focused on acquired cholesteatoma [1, 17, 18]. A relatively small number of studies have been published on congenital cholesteatoma. To the best of our knowledge, no prior studies have used proteomics to investigate congenital cholesteatoma pathogenesis.

Our study showed that protein spot 2-DE distribution patterns of congenital cholesteatoma are consistent among specimens and completely different from acquired cholesteatoma. Many proteins (127 spots) were exclusively expressed in congenital cholesteatoma, and not found in EAC skin or acquired cholesteatoma. Proteins that we did not expect to be expressed in fully differentiated epithelial cells were titin (gi|407139), forkhead transcription activator homolog...
Fig 3. Protein expression patterns in congenital cholesteatoma (left), acquired cholesteatomas (middle), and the retroauricular canal skin (right).

doi:10.1371/journal.pone.0137011.g003

Fig 4. Venn diagram showing the number of identified protein spots in each tissue. One hundred twenty seven spots were only expressed in congenital cholesteatoma.

doi:10.1371/journal.pone.0137011.g004
(FKH 5–3, gi|477361), ryanodine receptor 2 (cardiac), and isoform CRA_c (gi|119590477), all of which are expressed in mesodermal tissues [19–21].

Several theories have been proposed regarding congenital cholesteatoma origin, including the ‘epithelial rest theory’ [10], the ‘invagination theory’ [22, 23], and the ‘implantation theory’ [9]. Although it remains unclear which theory best describes congenital cholesteatoma etiology, all theories insist that congenital and acquired cholesteatoma have different origins. Acquired cholesteatoma generally arise from a pars flaccida retraction pocket.

Unexpected expression of non-epithelial protein in our experiments contradicts the epithelial rest theory where the congenital cholesteatoma arises from ectodermal derivatives from the first epibranchial placode, as found in various vertebrates. Among the 10 most abundant proteins exclusively expressed in congenital cholesteatoma tissues, FKH 5–3 was most interesting.

![Figure 5. Ten major spots only expressed in congenital cholesteatoma, as determined by image analysis.](doi:10.1371/journal.pone.0137011.g005)

### Table 2. 10 major protein exclusively expressed in congenital cholesteatoma.

| Spot No. | gi number  | Protein name | M_r  | PI    | % coverage | Matched peptide number |
|----------|------------|--------------|------|-------|------------|------------------------|
| 112      | gi|407139      | titin       | 524823| 8.06     | 10         | 28                     |
| 127      | gi|11493459    | PRO2619     | 58513 | 5.96     | 21         | 15                     |
| 128      | gi|477361      | FKH 5–3     | 12861 | 10.06    | 66         | 5                      |
| 132      | gi|119590477   | ryanodine receptor 2 (cardiac) isoform CRA_c | 568496 | 5.69     | 10         | 28                     |
| 272      | gi|119602578   | plecin 1 intermediate filament binding protein isoform CRA_c | 290791 | 5.62     | 14         | 41                     |
| 294      | gi|119581085   | keratin 10  | 63536 | 5.13     | 28         | 16                     |
| 385      | gi|186629      | keratin 10  | 39832 | 4.72     | 31         | 10                     |
| 447      | gi|119581085   | keratin 10  | 63536 | 5.13     | 30         | 16                     |
| 535      | gi|407139      | titin       | 524823| 8.06     | 11         | 29                     |
| 587      | gi|119624991   | leucine zipper protein 5 isoform CRA_b | 9456 | 11.70    | 72         | 8                      |

M_r, nominal mass; FKH, forkhead transcriptional factor; PI, calculated PI value; %coverage, sequence coverage; matched peptide number, number of mass values matched.

doi:10.1371/journal.pone.0137011.t002
Expression of this protein was also confirmed in congenital cholesteatoma by immunohistochemistry. Forkhead proteins, a family of transcription factors, play pathophysiologic roles in regulating expression of genes involved in cell growth, proliferation, differentiation, and longevity. Forkhead proteins regulate embryonic development mechanisms [24] and are expressed in hematopoietic stem cells that originate from the mesoderm and regulate lymphocyte development [20]. It has also been reported that forkhead transcription factors can be a downstream target of the Akt/PKB pathway, which is activated by microRNA 21 upregulation and subsequent apoptosis inhibition [25]. The presence of FKH 5–3 might indicate abnormal cell growth and be the pathogenic origin of congenital cholesteatoma.

Another distinctive finding of our study was expression of titin in congenital cholesteatoma. Titin is exclusively expressed in muscle [26] and originates from the mesoderm, where it plays a key role in vertebrate striated muscle assembly and function. Recent studies also found that titin is expressed in chromosomes and has functions related to oncogenesis [27–30]. We found that titin matched the major spots found in proteomic analysis on congenital cholesteatoma samples and was also strongly expressed in cholesteatoma matrices, as shown with immunostaining. The role of these proteins remain unclear in pathophysiology of congenital cholesteatoma, but we suggest it may be involved in congenital cholesteatoma cell proliferation.

Although several markers indirectly suggest pathogenic mechanisms of congenital cholesteatoma, our study has two main limitations. First, proteomics studies have inherent limitations. The amount of expression was determined only by image analysis, which could have differed if a more delicate experimental method was used. Therefore, there could be more abundant proteins that exclusively exist in congenital cholesteatoma. In addition, we only investigated the 10 most abundant spots identified in 2-DE analysis. However, there could be more important proteins that play a larger role in congenital cholesteatoma pathogenesis. We were only able to theorize congenital cholesteatoma pathogenic mechanisms using exclusive protein expression found by proteomic analysis. However, no information was gained on the role or importance of identified proteins in pathogenesis, which require animal models and/or in vitro cell culture systems. Second, limitations arose from working with harvested tissue.

Fig 6. Expression of forkhead transcriptional factor homolog (FKH 5–3, A) and titin (B) in congenital cholesteatoma, as detected with immunohistochemistry. Both proteins were well-expressed in cholesteatoma matrix. Negative controls (C, D) are also shown for comparison.

doi:10.1371/journal.pone.0137011.g006
Congenital cholesteatoma tissue forms a cystic pearl, which was properly washed. Therefore, there should have been little contamination from surrounding tissue. However, sample contamination by middle ear mucosa cannot be completely excluded in acquired cholesteatomas because acquired cholesteatomas are located in retraction pockets and strongly adhere to middle ear mucosa. There also could have been contamination with blood even though surface blood was removed by extensive tissue washing (5–6 times in normal saline until blood no longer visible).

Even with these limitations, our proteomic study on congenital cholesteatoma tissue provides some clues on cholesteatoma pathogenesis. It is tempting to speculate that the origin of congenital cholesteatomas differs from that of acquired cholesteatomas, which originate from tympanic membrane epithelium. This study provides justification for future research on congenital cholesteatoma pathogenesis.

Acknowledgments
We wish to acknowledge technical support from Yonsei Proteomic Research Center (www.proteomix.org).

Author Contributions
Conceived and designed the experiments: SHK JYC. Performed the experiments: SHS MH SHK. Analyzed the data: SHS MH SHK JYC. Contributed reagents/materials/analysis tools: JYC. Wrote the paper: SHS MH.

References
1. Maniu A, Harabagiu O, Perde Schrepler M, Catana A, Fanuta B, Mogoanta CA. Molecular biology of cholesteatoma. Rom J Morphol Embryo. 2014; 55(1):7–13.
2. Frankel S, Berson S, Godwin T, Han JC, Parisier SC. Differences in dendritic cells in congenital and acquired cholesteatomas. Laryngoscope. 1993; 103(11 Pt 1):1214–1217 PMID: 8231573
3. Olszewska E, Rutkowska J, Minovi A, Sieskiewicz A, Rogowski M, Dazert S. The Role of p21 and p53 Proteins in Congenital Cholesteatoma. Otol Neurotology. 2013; 34(2):266–274.
4. Park HR, Min SK, Min K, Jun SY, Seo J, Kim HJ. Increased expression of p63 and survivin in cholesteatomas. Acta Otolaryngol. 2009; 129(3):268–272. doi:10.1080/00016480802251591 PMID: 18615329
5. Kojima H, Miyazaki H, Shiwa M, Tanaka Y, Moriyama H. Molecular biological diagnosis of congenital and acquired cholesteatoma on the basis of differences in telomere length. Laryngoscope. 2001; 111 (5):867–873. PMID: 11359168
6. Bennett M, Warren F, Jackson GC, Kaylie D. Congenital cholesteatoma: theories, facts, and 53 patients. Otolaryng Clin N Am. 2006; 39(6):1081–1094.
7. Michaels L. Origin of congenital cholesteatoma from a normally occurring epidermoid rest in the developing middle ear. Int J Pediatr Otorhinolaryngol. 1988; 15(1):51–65.
8. Sade J, Babiacki A, Pinkus G. The metaplastic and congenital origin of cholesteatoma. Acta Otolaryngol. 1983; 96(1–2):119–129. PMID: 6193677
9. Friedberg J. Congenital cholesteatoma. Laryngoscope. 1994; 104(3 Pt 2):1–24. PMID: 8127199
10. Teed RW. Cholesteatoma verum tympani—Its relationship to the first epibranchial placode. Arch Otolaryngol. 1936; 24(4):455–474.
11. Karmody CS, Byahatti SV, Blevins N, Valtonen H, Northrop C. The origin of congenital cholesteatoma. Am J Otol. 1998; 19(3):292–7. PMID: 9596177
12. Michaels L. An epidermoid formation in the developing middle ear: possible source of cholesteatoma. J Otolaryngol. 1986; 15(3):169–174. PMID: 3723656
13. Akimoto R, Pawankar R, Yagi T, Baba S. Acquired and congenital cholesteatoma: determination of tumor necrosis factor-alpha, intercellular adhesion molecule-1, interleukin-1-alpha and lymphocyte functional antigen-1 in the inflammatory process. ORL J Otorhinolaryngol Relat Spec. 2000; 62(5):257–265. PMID: 10965261
14. Cho SY, Lee EY, Lee JS, Kim HY, Park JM, Kwon MS, et al. Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map. Proteomics. 2005; 5(13):3386–3396. PMID: 16047310

15. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996; 68(5):850–858. PMID: 8779443

16. Choi BK, Cho YM, Bae SH, Zoubaulis CC, Paik YK. Single-step perfusion chromatography with a throughput potential for enhanced peptide detection by matrix-assisted laser desorption/ ionization-mass spectrometry. Proteomics. 2003; 3(10):1955–1961. PMID: 14625858

17. Macias JD, Gerkin RD, Locke D, Macias MP. Differential gene expression in cholesteatoma by DNA chip analysis. Laryngoscope. 2013; 123(Suppl S5):S1–S21. doi: 10.1002/lary.24176 PMID: 23670528

18. Liu W, Yin T, Ren J, Li L, Xiao Z, Chen X, et al. Activation of the EGFR/Akt/NF-kappaB/cyclinD1 survival signaling pathway in human cholesteatoma epithelium. Eur Arch Otorhinolaryngol. 2014; 271(2):265–273. doi: 10.1007/s00405-013-2403-6 PMID: 23463347

19. Kotter S, Andresen C, Kruger M. Titin: central player of hypertrophic signaling and sarcomeric protein quality control. Biol Chemistry. 2014; 395(11):1341–1352.

20. Hromas R, Moore J, Johnston T, Socha C, Klemsz M. Drosophila forkhead homologues are expressed in a lineage-restricted manner in human hematopoietic cells. Blood. 1993; 81(11):2854–2859. PMID: 8499623

21. Mukherjee S, Thomas NL, Williams AJ. Insights into the gating mechanism of the ryanodine-modified human cardiac Ca²⁺-release channel (ryanodine receptor 2). Mol Pharmacol. 2014; 86(3):318–329. doi: 10.1124/mol.114.093757 PMID: 25002270

22. Ruedli L. Cholesteatoma formation in the middle ear in animal experiments. Acta Otolaryngol. 1959; 50(3–4):233–240. PMID: 13660782

23. Aimi K. Role of the tympanic ring in the pathogenesis of congenital cholesteatoma. Laryngoscope. 1983; 93(9):1140–1146. PMID: 6888124

24. Tuteja G, Kaestner KH. Forkhead transcription factors II. Cell. 2007; 131(1):192. PMID: 17923097

25. Friedland DR, Eernisse R, Erbe C, Gupta N, Cioffi JA. Cholesteatoma growth and proliferation: post-transcriptional regulation by microRNA-21. Otol Neurotol. 2009; 30(7):998–1005. doi: 10.1097/MAO.0b013e3181b4e91f PMID: 19672202

26. Granzier HL, Labert S. Titin and its associated proteins: the third myofilament system of the sarcomere. Adv Protein chem. 2005; 71:79–119. PMID: 16230110

27. Greenman C, Stephens P, Smith R, Daigleish GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153–158. PMID: 17344846

28. Machado C, Andrew DJ. D-Titin: a giant protein with dual roles in chromosomes and muscles. J Cell Biol. 2000; 151(3):639–652. PMID: 11062264

29. Machado C, Sunkel CE, Andrew DJ. Human autoantibodies reveal titin as a chromosomal protein. J Cell Biol. 1998; 141(2):321–333. PMID: 9548712

30. Zastrow MS, Flaherty DB, Benian GM, Wilson KL. Nuclear titin interacts with A- and B-type lamins in vitro and in vivo. J Cell Sci. 2006;119(Pt 2):239–249.